Clinical trial for people with Down syndrome who also have an immune skin condition

 
This study is designed to determine whether tofacitinib is a safe and effective treatment for immune skin conditions in adults with Down syndrome, and to further our understanding of the immune system in Down syndrome.

Tofacitinib is an FDA-approved drug currently used to treat arthritis and ulcerative colitis.

Who is eligible?
Adults with Down syndrome between the ages of 18 and 60 years who have at least one active skin condition such as:

• Alopecia areata affecting at least 25% of the scalp
• Moderate-to-severe atopic dermatitis or eczema
• Moderate-to-severe hidradenitis suppurativa or boils
• Moderate-to-severe psoriasis
• Moderate-to-severe vitiligo

What is involved?
Participants must attend eight study visits at the University of Colorado Anschutz Medical Campus during the 18-week trial and have a study partner available to attend the visits with them. A blood draw for safety monitoring is required at each visit. Participants will be given tofacitinib at no cost for the duration of the study.

This trial is supported by a grant from the National Institute of Arthritis, Musculoskeletal and Skin Diseases (Grant #R61AR077495) and the Linda Crnic Institute for Down Syndrome. Learn more at bit.ly/TofainDS or on clinicaltrials.gov (NCT04246372).

COMIRB#: 19-1362
PI: Joaquín Espinosa